methyl 4,4-dimethoxypentanoate | 52128-61-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4,4-dimethoxypentanoate
• CAS: 52128-61-7
• 化学式: C₈H₁₆O₄
• 分子量: 176.213
• InChiKey: LJUGGVUDXRWTGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4,4-dimethoxypentanoate 在 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以100%的产率得到乙酰丙酸甲酯
  参考文献：
  名称：

  RUTHENIUM HYDRIDE-CATALYZED DOUBLE BOND MIGRATION OF 2,5-DIMETHOXY-2,5-DIHYDROFURANS. A NEW PROCESS FOR THE PREPARATION OF γ-KETOESTERS

  摘要：

  γ-酮酯通过以铑氢化合物 HRuCl(PPh3)3(C6H5CH3) 或 HRuCl(CO)(PPh3)3 为催化剂的 2,5-二甲氧基-2,5-二氢呋喃的双键迁移反应获得，随后在酸性介质中水解，产率极高。

  DOI：

  10.1246/cl.1982.23
• 作为产物：
  描述：

  (Z)-3-chloro-4-methoxy-pent-3-en-2-one 以 甲醇 为溶剂， 生成 methyl 4,4-dimethoxypentanoate
  参考文献：
  名称：

  Verhe,R. et al., Bulletin des Societes Chimiques Belges, 1978, vol. 87, p. 143 - 152

  摘要：

  DOI：

文献信息

• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• From Renewable Levulinic Acid to a Diversity of 3-(Azol-3-yl)Propanoates
  作者：Alex F. C. Flores、Luciana A. Piovesan、Lucas Pizzuti、Darlene C. Flores、Juliana L. Malavolta、Marcos A. P. Martins

  DOI：10.1002/jhet.1774

  日期：2014.5

  3‐(trihalomethylated‐1,2‐azol‐3‐yl)propanoate is reported. Preparation of the key methyl 7,7,7‐trihalo‐4‐methoxy‐6‐oxohept‐4‐enoate precursors from levulinic acid is also described. The synthetic potential of this synthetic protocol was indicated by the production of several methyl and ethyl 3‐(isoxazol‐3‐yl)propanoates and 3‐(1H‐pyrazol‐3‐yl)propanoates, and the respective acid derivatives, in good (70–95%)

  将7,7,7-三氟-4-甲氧基-6-氧代-4-庚烯酸甲酯和7,7,7-三氯-4-甲氧基-6-氧代-4-庚烯酸甲酯高效杂环化为异恶唑和吡唑衍生物代表报告了一种新型的谷氨酸样3-（三卤代甲基化1,2-氮杂-3-基）丙酸酯。还描述了从乙酰丙酸制备关键的7,7,7-三卤代-4-甲氧基-6-氧杂庚酸酯-甲基丙烯酸甲酯前体。这种合成规程的合成潜力通过生产3-（异恶唑-3-基）丙酸甲酯和乙酯和3-（1H-吡唑-3-基）丙酸酯和相应的酸衍生物来表明。 （70–95％）的产量。5-（3-乙氧基-3-氧丙基）-1 H-吡唑-3-羧酸乙酯的晶体结构（10c）是通过单晶X射线衍射分析确定的。N–H … H分子间氢键将分子连接到分解异构体中。
• HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20130196964A1

  公开（公告）日：2013-08-01

  The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有杂环取代基的新型芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步治疗措施结合使用。
• A CONVENIENT METHOD FOR THE SYNTHESIS OF δ-ALKOXY-β-KETOESTER THE TITANIUM TETRACHLORIDE-ACTIVATED REACTION OF DIKETENE WITH ACETAL
  作者：Toshio Izawa、Teruaki Mukaiyama

  DOI：10.1246/cl.1974.1189

  日期：1974.10.5

  It was established that, in the presence of TiCl4, diketene [1] reacts with acetals [2] at −78∼−20°C to afford δ-alkoxy-β-ketoesters [3] in good yields. This reaction provides a novel method for the introduction of –COCH2COCH2– unit to an electrophile as acetal activated by TiCl4.

  已经确定，在 TiCl4 存在下，双烯酮 [1] 与缩醛 [2] 在 -78~-20°C 反应以良好的产率提供 δ-烷氧基-β-酮酯 [3]。该反应提供了一种将–COCH2COCH2–单元作为由TiCl4活化的缩醛引入亲电子试剂的新方法。